Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Medicare coverage of CTC for seniors needed

President Obama, in his first routine physical exam as commander in chief, received a CT colonography (CTC), commonly known as a virtual colonoscopy, to screen him for colorectal cancer. However, Obama Administration officials at the Centers for Medicare and Medicaid Services (CMS) previously denied coverage of the same exam for seniors enrolled in Medicare, cutting off access for many to an exam proven to increase compliance with nationally accepted colon cancer screening guidelines.

3 Mar 2010

Common diabetes therapies may increase cancer risk, but more research needed

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.

3 Mar 2010

ASGE and TV actor encourage African-Americans to undergo screening for colon cancer

CSI: New York actor Hill Harper has joined forces with the American Society for Gastrointestinal Endoscopy (ASGE), representing doctors who specialize in endoscopy and colon cancer screening, in a new Public Service Announcement (PSA) to encourage African-Americans to undergo screening for colon cancer

3 Mar 2010

ArQule reports net loss of $36,136,000 for 2009

ArQule, Inc. today announced its financial results for the year and for the fourth quarter ended December 31, 2009.

2 Mar 2010

Future work may uncover links between insulin use and cancer risk, say researchers

2 Mar 2010

Colonoscopy screening recommended for people with family history of colon cancer

A family history of colon cancer, also known as colorectal cancer or CRC, puts people at higher than average risk for developing the disease.

2 Mar 2010

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

Celsion Corporation today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study.

2 Mar 2010

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation for its compound perifosine from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for the treatment of multiple myeloma.

1 Mar 2010

Gene signature may help identify risk of colon cancer recurrence

A gene signature, first identified in mouse colon cancer cells, may help identify patients at risk of colon cancer recurrence, according to a recent study by Vanderbilt-Ingram Cancer Center researchers.

26 Feb 2010

Colonoscopies performed by non-gastroenterologists may increase risk of developing subsequent CRC

Following a negative complete colonoscopy, those who had their colonoscopies at a hospital and had their procedures performed by a non-gastroenterologist may be at a significantly increased risk of developing subsequent colorectal cancer (CRC), according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute.

24 Feb 2010

AGA conference highlights emerging technologies for digestive and metabolic disorders

The American Gastroenterological Association (AGA) is taking the lead in gastroenterological innovation by conducting "Fostering Innovation and Technology in Digestive and Metabolic Diseases."

24 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

CINJ researchers test malaria drug for colorectal cancer treatment

While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.

23 Feb 2010

Researchers use Life Technologies’ next-generation sequencing instruments for cancer research

Life Technologies Corporation today announced the publication of two key scientific papers that highlight the utility of next-generation sequencing instruments in better understanding disease and the genetic differences that cause diversity within and between human populations. The Applied Biosystems SOLiD™ System was used in both of these research studies.

19 Feb 2010

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Van Andel Research Institute researchers have found a way to reverse resistance to sunitinib, a treatment that is currently the first line of defense against clear cell renal cell carcinoma (ccRCC), a deadly form of kidney cancer. Most patients who show a positive response to sunitinib develop a resistance to the drug after one year of treatment.

19 Feb 2010

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

Scientists at the Johns Hopkins Kimmel Cancer Center have used data from the whole genome sequencing of cancer patients to develop individualized blood tests they believe can help physicians tailor patients' treatments. The genome-based blood tests, believed to be the first of their kind, may be used to monitor tumor levels after therapy and determine cancer recurrence.

19 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

Northern California Cancer Center becomes Cancer Prevention Institute of California

As the only organization in the country dedicated solely to cancer prevention research, the Northern California Cancer Center has changed its name to the Cancer Prevention Institute of California. The new name immediately communicates the organization's critical mission to prevent cancer and reflects its service to the entire state of California.

18 Feb 2010

Medical journal finds divide between doctors and patients on new mammogram recommendations

News outlets explore confusion about cancer screening guidelines and questions raised about the effects of high tech procedures on health care costs and quality.

17 Feb 2010

GeneNews granted second U.S. patent for Sentinel Principle technology

GeneNews Limited, a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has been granted a second U.S. patent for its core platform technology, the Sentinel Principle(R). U.S. Patent # 7,662,558, entitled "Method of profiling gene expression in a human subject."

17 Feb 2010

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Medicare coverage of CTC for seniors needed

Common diabetes therapies may increase cancer risk, but more research needed

ASGE and TV actor encourage African-Americans to undergo screening for colon cancer

ArQule reports net loss of $36,136,000 for 2009

Future work may uncover links between insulin use and cancer risk, say researchers

Colonoscopy screening recommended for people with family history of colon cancer

Celsion to commence Phase II Study of ThermoDox and RFA for CRLM

COMP issues positive opinion for Æterna Zentaris' perifosine orphan medicinal product designation

Gene signature may help identify risk of colon cancer recurrence

Colonoscopies performed by non-gastroenterologists may increase risk of developing subsequent CRC

AGA conference highlights emerging technologies for digestive and metabolic disorders

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

CINJ researchers test malaria drug for colorectal cancer treatment

Researchers use Life Technologies’ next-generation sequencing instruments for cancer research

VARI researchers find ways to reverse resistance to sunitinib: Patients with ccRCC show positive response

Johns Hopkins Kimmel Cancer Center scientists develop genome-based blood tests for cancer

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Northern California Cancer Center becomes Cancer Prevention Institute of California

Medical journal finds divide between doctors and patients on new mammogram recommendations

GeneNews granted second U.S. patent for Sentinel Principle technology

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in